Terminal
Spotlight
Cashu Research

← Back to Terminal

Stocks
Healthcare
NASDAQ
GOSS

Market Cap: $57.38M

GI

Gossamer Bio, Inc.

GOSS

NASDAQUSD

Overview News Analyst Reports Financials Politician Trades Insider Trades Executive

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

Stocks About Advertisers Brokers Contact

Legal

Terms of Service Privacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

News

Gossamer Bio Incentivizes Talent Acquisition with New Stock Options for Pulmonary Hypertension Treatment

Gossamer Bio's Strategic Incentives for Talent Acquisition in Pulmonary Hypertension Treatment Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies…

Cashu Finance·over 1 year ago

Gossamer Bio Boosts Workforce with Stock Options to Attract Top Talent

Gossamer Bio Strengthens Workforce with Stock Option Grants Gossamer Bio, Inc., a clinical-stage biopharmaceutical company specializing in treatments for pulmonary hypertension, announces the approval…

Cashu Finance·almost 2 years ago

Gossamer Bio Enhances Workforce Strategy Amid Innovations in Pulmonary Hypertension Treatments

Gossamer Bio Advances Talent Acquisition Strategy Amid Clinical Innovations Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, is making strategic moves to strengthen its workforce as it…

Cashu Finance·almost 2 years ago

Gossamer Bio Invests in Talent Acquisition with Stock Options for New Employees

Gossamer Bio's Commitment to Talent Acquisition in Biopharmaceuticals Gossamer Bio, Inc. is making strides in the biopharmaceutical sector with a focused commitment to developing innovative treatments…

Cashu Finance·almost 2 years ago

Gossamer Bio Advances Pulmonary Hypertension Research with Strong Financial Position

Gossamer Bio Advances Pulmonary Hypertension Research Amid Promising Financial Outlook Gossamer Bio, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for p…

Cashu Finance·almost 2 years ago

Gossamer Bio's Strategic Growth in Pulmonary Hypertension Treatments and Financial Stability

Gossamer Bio Charts a Course for Pulmonary Hypertension Advancements Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for pulmonary arterial hypertensio…

Cashu Finance·almost 2 years ago